Results for tag: "Pulmonary Hypertension Associated With Interstitial Lung Disease Drug"

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) is a rare and complex form of pulmonary hypertension (PH) caused by a variety of interstitial lung diseases (ILDs). PH-ILD is characterized by an increase in pulmonary vascular resistance, leading to an elevation in pulmonary artery pressure. This can lead to right heart failure and death. Treatment of PH-ILD is challenging and requires a combination of therapies, including lifestyle modifications, oxygen therapy, and medications. Medications used to treat PH-ILD include prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and calcium channel blockers. These medications are used to reduce pulmonary vascular resistance, improve exercise capacity, and reduce symptoms. The PH-ILD drug market is composed of a variety of companies, including Actelion Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics. These companies are focused on developing and commercializing medications to treat PH-ILD. Show Less Read more